David M. Gau

This study identifies survivin as a key oncogenic driver in renal cell carcinoma, showing its roles in cell cycle, migration, and mitochondrial function, and suggests it as a therapeutic target.

This study shows that loss of Profilin1 reduces plasma membrane PIP2 levels, linking actin regulation to PIP2 homeostasis and revealing Pfn1's broader role in lipid metabolism.

This study shows that microplastics impair macrophage bioenergetics and immune function, reducing antigen presentation and increasing disease susceptibility.

This study identifies Profilin-1 as a driver of chromophobe renal cell carcinoma progression by promoting proliferation, invasion, and resistance to oxidative stress.

This study shows that a small molecule Pfn1 inhibitor reduces tumor angiogenesis in renal cell carcinoma by targeting endothelial cell Pfn1.

This study shows that TLR9 sensing of tissue damage during influenza infection promotes inflammation and antiviral responses, but its absence leads to impaired viral clearance and prolonged lung injury.

This study shows that MRTF in breast cancer cells promotes osteoclast differentiation via paracrine signaling, enhancing bone metastasis, and suggests MRTF inhibition as a potential therapeutic strategy.

This study identifies the MRTFA/SRF pathway as a regulator of quiescence in cancer and shows that inhibiting it induces quiescence and reduces tumor growth.

This study identifies mDia2 as a mediator of MRTF-A-dependent breast cancer cell migration and links MRTF activity to malignancy, suggesting it as a therapeutic target.

This study shows that partial loss of Profilin1 in vascular endothelial cells has some protective effects against atherosclerosis but is not enough to fully prevent it.